Abstract
This review presents sleep disturbances and their underlying pathophysiology in three categories of neurodegenerative disorders namely tauopathies, synucleinopathies, and Huntingtons disease (HD) and prion-related diseases. Sleep abnormalities are a major and early feature of neurodegenerative disorders, especially for synucleinopathies, HD and prion-related diseases, in which the sleep-related brainstem regions are severely altered and impaired sooner than in most of the tauopathies. In synucleinopathies, HD and prion-related diseases, specific sleep disturbances, different from those observed in tauopathies, are considered as core manifestations of the disease and in some cases, as preclinical signs. For this reason, the evaluation of sleep components in these neurodegenerative disorders may be useful to make a diagnosis and to assess the efficacy of pharmacotherapy. Since sleep disruption may occur early in the course of neurodegeneration, sleep disturbance may serve as groundwork to study the efficacy of neuroprotective agents to prevent or delay the development of a full-blown neurodegenerative disorder. The cause of sleep disturbances in neurodegenerative disorders may be attributed to several factors, including age-related modifications, symptoms of the disease, comorbid conditions and the neurodegenerative process itself.
Keywords: Neurodegenerative disorders, sleep, electroencephalography, tauopathies, synucleinopathies, prion-related diseases, Alzheimer's disease, Parkinson's disease
Current Pharmaceutical Design
Title: Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Volume: 14 Issue: 32
Author(s): J.-F. Gagnon, D. Petit, V. Latreille and J. Montplaisir
Affiliation:
Keywords: Neurodegenerative disorders, sleep, electroencephalography, tauopathies, synucleinopathies, prion-related diseases, Alzheimer's disease, Parkinson's disease
Abstract: This review presents sleep disturbances and their underlying pathophysiology in three categories of neurodegenerative disorders namely tauopathies, synucleinopathies, and Huntingtons disease (HD) and prion-related diseases. Sleep abnormalities are a major and early feature of neurodegenerative disorders, especially for synucleinopathies, HD and prion-related diseases, in which the sleep-related brainstem regions are severely altered and impaired sooner than in most of the tauopathies. In synucleinopathies, HD and prion-related diseases, specific sleep disturbances, different from those observed in tauopathies, are considered as core manifestations of the disease and in some cases, as preclinical signs. For this reason, the evaluation of sleep components in these neurodegenerative disorders may be useful to make a diagnosis and to assess the efficacy of pharmacotherapy. Since sleep disruption may occur early in the course of neurodegeneration, sleep disturbance may serve as groundwork to study the efficacy of neuroprotective agents to prevent or delay the development of a full-blown neurodegenerative disorder. The cause of sleep disturbances in neurodegenerative disorders may be attributed to several factors, including age-related modifications, symptoms of the disease, comorbid conditions and the neurodegenerative process itself.
Export Options
About this article
Cite this article as:
Gagnon J.-F., Petit D., Latreille V. and Montplaisir J., Neurobiology of Sleep Disturbances in Neurodegenerative Disorders, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549353
DOI https://dx.doi.org/10.2174/138161208786549353 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anthony L. Fink (1943-2008): Scientist, Teacher and Artist
Current Protein & Peptide Science SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Hierarchical Profiles of Signaling Pathways and Networks Reveal Two Complementary Pharmacological Mechanisms
CNS & Neurological Disorders - Drug Targets Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research Ghrelin Receptor Signaling: A Promising Therapeutic Target for Metabolic Syndrome and Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design